乳腺癌原发灶及淋巴结转移灶中P-gp、GST-π、TopoⅡ的表达及临床意义  

Expression and Clinical Significance of P-gp、GST-π and TopoⅡin Breast Cancer and Their Lymph-node Metastasis Tumors

作　　者：张静[1] 宁殿宾[1] 赵玉哲[1] 邢颖[1] 曹文庆[1] 巩涛[1] 王跃欣[1] 

机构地区：[1]河北省人民医院腺体外科,石家庄050051

出　　处：《肿瘤防治研究》2008年第3期181-183,共3页Cancer Research on Prevention and Treatment

摘　　要：目的探讨乳腺癌原发灶和淋巴结转移灶中P-gp、GST-π、TopoⅡ的表达及相关性。方法选择2005年1～12月所有在我科行手术治疗的乳腺癌患者70例,其中有腋下淋巴结转移的36例,无腋下淋巴结转移的34例,用免疫组化SP法检测原发灶和淋巴结转移灶P-gp、GST-π、TopoⅡ的表达。结果(1)有腋下淋巴结转移的乳腺癌中P-gp、GST-π的表达高于无腋下淋巴结转移的乳腺癌(P=0.043、P=0.012),TopoⅡ的表达两者间差异无统计学意义。(2)乳腺癌原发灶和淋巴结转移灶的GST-π、TopoⅡ表达有相关性(P=0.001、P=0.01),P-gp的表达无相关性。结论(1)P-gp、GST-π高表达与腋下淋巴结转移显著相关。(2)乳腺癌原发灶与淋巴结转移灶的耐药性不尽一致。Objective To investigate the protein expressions and relationship of P-gp, GST-π and Topo Ⅱ in breast cancer and their lymph-node metastasis tumor. Methods High sensitive SP immunohistochemical method was used to detect the protein expressions of P-gp,GST-π and Topo Ⅱ in 70 breast cancers and their lymph-node metastasis tumors（36 with lymphatic metastasis）. Results （1） The expressions of P- gp, GST-π in breast cancers with lymphatic metastasis was higher than those without lymphatic metastasis（P= 0. 043,P= 0. 012）,hut the expression of Topo Ⅱ had no difference between the two groups. （2） The expressions of GST-π,ToPo Ⅱ were significantly associated with lymphatic metastasis （P = 0. 001, P = 0. 01 ）. However, the expression of P-gp was not associated with lymphatic metastasis. Conclusion （1） There was a significant relationship between the higher expression of P-gp, GST-π and the axillary lymph node involvement. （2） The drug-resistance of breast cancers was not as same as their lymph-node metastatic tumors.

关 键 词：多药耐药 P-糖蛋白 谷胱甘肽-S-转移酶-Π 拓扑异构酶Ⅱ 

分 类 号：R737.9[医药卫生—肿瘤]